Acrobiosystems Co

Acrobiosystems Co EBITDA Margin

The EBITDA Margin of Acrobiosystems Co (301080.SZ) as of Oct 20, 2026 is 23.50 %. In the previous year, EBITDA Margin was 23.28 % — a change of 0.94% (higher).

EBITDA Margin

23.50 %

YoY

0.94%

Last updated:

EBITDA Margin of Acrobiosystems Co is 2025 23.50 % . EBITDA Margin of Acrobiosystems Co was 2024 23.28 % . It decreases by 0.94% higher compared to the previous year.

The Acrobiosystems Co EBITDA Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Margin
Date
EBITDA Margin
Jan 1, 2018
18.13 CNY
Jan 1, 2019
17.86 CNY
Jan 1, 2020
58.34 CNY
Jan 1, 2021
53.50 CNY
Jan 1, 2022
40.00 CNY
Jan 1, 2023
29.77 CNY
Jan 1, 2024
23.28 CNY
Jan 1, 2025
23.50 CNY
The Acrobiosystems Co EBITDA Margin history
YEAREBITDA MarginYoY
23.50 %+0.94%
23.28 %-21.80%
29.77 %-25.57%
40.00 %-25.23%
53.50 %-8.30%
58.34 %+226.59%
17.86 %-1.44%
18.13 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Acrobiosystems Co Stock analysis

What does Acrobiosystems Co do? Acrobiosystems Co Ltd develops biomedicine and bio-protein technology, focusing on recombinant proteins, detection services, kits, antibodies, fillers, and culture media. The company serves R&D and production sectors for drug discovery, screening, diagnostic reagents, and clinical trials across tumor, autoimmune, cardiovascular, and infectious disease areas. Its products support early drug development stages and process control in pharmaceutical manufacturing. The firm's main customers are pharmaceutical companies and research institutions requiring advanced biotech solutions for disease treatment development. The company generates revenue through the sale of recombinant proteins, detection services, and related products like kits and antibodies. These offerings are tailored for pharmaceutical firms engaged in drug development and diagnostic reagent optimization. Acrobiosystems' product portfolio targets the biopharmaceutical industry, specifically addressing needs in tumor, autoimmune, cardiovascular, and infectious disease research. The firm's services are utilized in preclinical and clinical trial phases to enhance drug development efficiency. Acrobiosystems' main products include recombinant proteins, kits, antibodies, fillers, and culture media, which are sold to pharmaceutical companies and research organizations. These entities use the products for early-stage drug discovery, verification, and optimization processes. The company's detection services support diagnostic reagent development and drug screening, directly contributing to the pharmaceutical R&D pipeline. The firm's focus on CMC (process control) for drug production ensures its offerings align with critical manufacturing stages in biopharmaceutical development. Acrobiosystems Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Acrobiosystems Co stock

EBITDA Margin of Acrobiosystems Co is 23.50 % in 2025.

EBITDA Margin of Acrobiosystems Co changed from 23.28 % to 23.50 %, representing a 0.94% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA Margin Acrobiosystems Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA Margin shows what percentage of revenue converts to EBITDA. It normalizes for depreciation and capital structure differences.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBITDA Margin's Acrobiosystems Co with sector peers and the industry average to assess whether it is attractive.

To evaluate EBITDA Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBITDA Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Acrobiosystems Co

All Key Metrics — Acrobiosystems Co